INS and Hypoglycemia: Consistent with this notion, metoclopramide (Teva Pharmaceutical Industries Ltd., United States), a dopamine (D2), receptor antagonist, was shown to improve both hypoglycemia awareness and counterregulatory hormone responses in response to insulin-induced hypoglycemia (Vieira De Abreu et al., 2018; Devore et al., 2022).